Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D07VIB
|
|||
| Former ID |
DNCL001894
|
|||
| Drug Name |
Tecarfarin
|
|||
| Synonyms |
ATI-5923
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Cerebrovascular ischaemia [ICD-11: 8B1Z; ICD-10: I67.8; ICD-9: 434.91] | Phase 3 | [1] | |
| Thrombosis [ICD-11: DB61-GB90; ICD-10: I80-I82] | Phase 3 | [2] | ||
| Company |
ARYx Therapeutics
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C21H14F6O5
|
|||
| Canonical SMILES |
CC(C(F)(F)F)(C(F)(F)F)OC(=O)C1=CC=C(C=C1)CC2=C(C3=CC=CC=C3OC2=O)O
|
|||
| InChI |
1S/C21H14F6O5/c1-19(20(22,23)24,21(25,26)27)32-17(29)12-8-6-11(7-9-12)10-14-16(28)13-4-2-3-5-15(13)31-18(14)30/h2-9,28H,10H2,1H3
|
|||
| InChIKey |
QFLNTQDOVCLQKW-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 867257-26-9
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Vitamin K epoxide reductase complex 1 (VKORC1) | Target Info | Inhibitor | [3] |
| KEGG Pathway | Ubiquinone and other terpenoid-quinone biosynthesis | |||
| Pathwhiz Pathway | Vitamin K Metabolism | |||
| Coagulation | ||||
| WikiPathways | PTM: gamma carboxylation, hypusine formation and arylsulfatase activation | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02522221) Tecarfarin Anti-Coagulation Trial (TACT). | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | Tecarfarin, a novel vitamin K reductase antagonist, is not affected by CYP2C9 and CYP3A4 inhibition following concomitant administration of fluconazole in healthy participants. J Clin Pharmacol. 2011Apr;51(4):561-74. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.